Anthony Mancini
Insider (Form 4 reporting owner): See Remarks CIK 2124509Name as filed: Mancini AnthonyIts filings on EDGARAll insiders
Measures activity, not value. Not investment advice.
Since 25 Mar 2026, sold $10.4M in 10 sales (9 under a 10b5-1 plan set in advance) of Revolution Medicines.
Companies
Role on the latest Form 4 for each; open-market trades counted| Company | Role | Trades from | to | Purchases | Sales |
|---|---|---|---|---|---|
| Revolution Medicines RVMD | See Remarks | 25 Mar 2026 | 9 Nov 2026 | – | 10$10.4M |
What the share price did after their trades Share price return after each open-market trade, from the first close after the Form 4 became public, minus the return of the company's sector fund (the S&P 500 fund when the sector has none) over the same days. Median over the trades, in percentage points; at most one trade per company, side and month. It describes the past.
Median return minus the sector fund, in percentage points; "too few trades" under 5| Open-market trades | After 3 months | After 6 months | After 12 months |
|---|---|---|---|
| After sales | too few trades4 trades | too few trades2 trades | no trade old enough |
For a sale, a negative number means the shares did worse than the sector afterwards. It describes the past, not what comes next.
By year
Counted open-market trades, by trade date| Year | Purchases | Bought | Sales | Sold | Net |
|---|---|---|---|---|---|
| 2026 | – | – | 10 | $10.4M | -$10.4M |
Every trade
10, newest first; open-market purchases and sales only| Trade date | Company | Side | Shares | Price | Value | Planned Rule 10b5-1 plan: the insider set the trade up in advance, so its timing says less about their view. The box exists on Form 4 since April 2023. | Filing |
|---|---|---|---|---|---|---|---|
| 9 Nov 2026 | Revolution Medicines RVMD | Sellafter exercising options | 811 | $200.00 | $162K | 10b5-1 plan | Form 4filed 12 Nov 2026 |
| 26 Oct 2026 | Revolution Medicines RVMD | Sellafter exercising options | 2,310 | $186.99 | $432K | 10b5-1 plan | Form 4filed 28 Oct 2026 |
| 24 Sep 2026 | Revolution Medicines RVMD | Sellafter exercising options | 3,708 | $200.45 | $743K | 10b5-1 plan | Form 4filed 28 Sep 2026 |
| 18 Sep 2026 | Revolution Medicines RVMD | Sell | 1,764 | $196.94 | $347K | 10b5-1 plan | Form 4filed 22 Sep 2026 |
| 16 Sep 2026 | Revolution Medicines RVMD | Sell | 1,774 | $199.24 | $353K | 10b5-1 plan | Form 4filed 18 Sep 2026 |
| 10 Sep 2026 | Revolution Medicines RVMD | Sellafter exercising options | 15,448 | $204.16 | $3.2M | 10b5-1 plan | Form 4filed 14 Sep 2026 |
| 16 Jun 2026 | Revolution Medicines RVMD | Sell | 4,615 | $156.12 | $720K | No | Form 4filed 18 Jun 2026 |
| 26 May 2026 | Revolution Medicines RVMD | Sellafter exercising options | 3,121 | $153.99 | $481K | 10b5-1 plan | Form 4filed 28 May 2026 |
| 27 Apr 2026 | Revolution Medicines RVMD | Sellafter exercising options | 3,120 | $132.41 | $413K | 10b5-1 plan | Form 4filed 29 Apr 2026 |
| 25 Mar 2026 | Revolution Medicines RVMD | Sellafter exercising options | 37,450 | $95.57 | $3.6M | 10b5-1 plan | Form 4filed 26 Mar 2026 |
From Form 4: open-market purchases (code P) and sales (code S) only; awards, option exercises, tax withholding and gifts are not counted. Greyed rows are amended copies or another filer's report of the same trade and count nowhere. Measures activity, not value. Not investment advice.